Company
Company

Relevant Interviews, Disease and Trial Updates and Stock-Markets News posted by CRISPR Medicine News.

Check also Companies to Follow in 2022 and CMN Markets for the latest stock and market trends.

Always stay updated with the free CMN Newsletter.

Pfizer

Main (gene editing) focus: In vivo base editing for genetic diseases

Company stage: Commercial

Diseases (gene editing): Rare genetic diseases of the liver, muscle and central nervous system

Genome editing tool: Base editing

Funding stage: Public (NASDAQ:PFE)

Location: New York City, New York, USA

Website: https://www.pfizer.com/

Pipeline: https://www.pfizer.com/science/drug-product-pipeline

Gene editing partnerships: Beam Therapeutics

Pfizer is an established big pharma company with worldwide operations and drug discovery activities within many different areas. The company's engagement in the gene-editing space comes through its collaboration with Beam Therapeutics. The two companies will develop novel in vivo gene-editing programmes against targets within disease areas involving the liver, muscle and central nervous system (CNS).

Tags

HashtagPfizer

Company: Pfizer
Jobs, banner ads, webinars, sponsored content...
close
Search CRISPR Medicine